1.The report on the case of pregabalin has been successful for chronic cough associated with metastatic lung tumor
Miho Kojima ; Hiroaki Watanabe ; Yoshimi Okumura ; Rumiko Muraji ; Akiko Kumon ; Yuko Deguchi ; Shigeki Hirano
Palliative Care Research 2015;10(1):515-518
Purpose:Chronic cough is one of the symptoms that lead to a reduction in the quality of life insomnia, such as the decline in physical strength. For chronic cough due to metastatic lung tumors, and we experienced an example of after use pregabalin, showed a reduction of symptoms. Case:This case is a 75-year-old man. Abdominoperineal rectal amputation was performed in rectal cancer. Adjuvant chemotherapy has been performed, but multiple lung metastases appeared one year after surgery. Chemotherapy was continued, but lung metastases progressed, it became the policy of anti-cancer treatment ended 4 months after 2 years after surgery. Cough worsened since then, it was referred introduced to palliative care department. Because we thought respiratory tract irritation increased by organic disease is the cause, it starts from 50 mg/day pregabalin, it was increased by 25~50 mg while aware of potential side effects, such as drowsiness during the day. Cough relief at 125 mg/day, night sleep wasalso secure and possible. Conclusion:Pregabalin which is effective in neuropathic pain, there is a possibility that the suppression of hyperexcitability of nerve cells that are its pharmacological action, is also effective in chronic cough, it becomes choice of antitussive different mechanisms of action and opioid there is a possibility that may.
2.Decision-making support for cancer patients and their families at a palliative care clinic in a designated regional cancer care hospital
Hiroaki Watanabe ; Miho Kojima ; Yoshimi Okumura ; Yuki Kato ; Yuko Deguchi ; Shigeki Hirano
Palliative Care Research 2015;10(1):324-328
Objective:There are few reports on decision-making support at palliative care clinics in designated regional cancer care hospitals. This study clarified the types of decisionmaking support patients with cancer and their families were provided by specialized outpatient palliative care services. Method:We retrospectively examined the medical records of 110 patients who had been referred to the palliative care clinic for home care between April 2012 and March 2014. Results:The median duration of receiving services from the palliative care clinic was 23 days(range:1~492 days). The mean number of visits to the clinic was 4.7 visits(range:1~29 visits). A total of 89 patients(80%)needed decision-making support. Of those 89 patients, 33(30%)required support in making a decision about anticancer treatment. Twenty-six(78%)of those 33 patients had just received the diagnosis or were receiving anticancer treatment. Conclusion:The study suggested that decision-making support in early stages is an important role for a palliative care clinic in a designated regional cancer care hospital.
3.Heparin Anticoagulation during Cardiopulmonary Bypass for Thoracoabdominal Aorta Replacement in a Patient with a History of Heparin-Induced Thrombocytopenia
Masanao Ohba ; Hirokazu Murayama ; Hiroyuki Kito ; Kozo Matsuo ; Naoki Hayashida ; Souichi Asano ; Masao Hirano ; Shigeki Miyata
Japanese Journal of Cardiovascular Surgery 2010;39(3):144-147
Immune heparin-induced thrombocytopenia (HIT) is a crucial side effect of heparin therapy. We report the case of a 52-year-old man who was strongly suspected of having HIT after urgent descending aorta replacement. This case required continuous hemodiafiltration (CHDF) anticoagulated with unfractionated heparin (UFH) for acute renal failure after the operation. The patient developed thrombocytopenia and thrombus emphraxis in the circuit on the seventh day and was suspected of having HIT. UFH was ceased and replaced with argatroban. After then, thrombus emphraxis was not seen in the circuit and the platelet count was recovered promptly. He tested positive in an enzyme-linked immunosorbent assay for anti-platelet factor 4/heparin antibodies (anti-PF4/H Abs). Six months later, we found, an expanding thoracoabdominal aortic aneurysm and performed thoracoabdominal aorta replacement. We selected heparin anticoagulation for cardiopulmonary bypass because anti-PF4/H Abs were negative at that time. Thrombus emphraxis was not found during the operation. The patient developed neither thrombocytopenia nor thrombosis in the perioperative period.
4.Evaluation of the effect of analgesics for cancer patients using their pain descriptions
Kikuyo Nishida ; Yukio Toyama ; Kumi Kuno ; Shigeki Hirano ; Yuko Deguchi ; Yuiko Matsuda ; Takashi Watanabe ; Chie Yamazeki ; Yukari Itakura ; Hiroko Saito ; Takaaki Hasegawa
Palliative Care Research 2009;4(1):207-213
Purpose: The present study aims to evaluate the effect of analgesics in cancer patients based on their pain descriptions. Methods: The relationship between the words that patients used to describe their pain due to cancer and the efficacy of treatment with analgesics such as non-steroidal anti-inflammatory drugs (NSAIDs) or opioids was evaluated. Results: We recorded 529words that were used by 164patients to describe their pain and pain quality and classified them into 108types of pain.For patients who used the actual word 'dull' or one with a similar meaning, treatment with opioids was effective. However, treatment with opioids was less effective in patients who used words such as "numb" and "tingling". Conclusion: We were able to gain a good understanding of cancer pain by listening to the actual words that patients used when complaining of pain. These findings suggested that we could choose a suitable medication through evaluation of the actual words cancer patients used to describe their pain and successfully relieve their pain. Palliat Care Res 2009: 4(1): 207-213
5.Immunomodulatory Effects of Ambroxol on Airway Hyperresponsiveness and Inflammation.
Katsuyuki TAKEDA ; Nobuaki MIYAHARA ; Shigeki MATSUBARA ; Christian TAUBE ; Kenichi KITAMURA ; Astushi HIRANO ; Mitsune TANIMOTO ; Erwin W GELFAND
Immune Network 2016;16(3):165-175
Ambroxol is used in COPD and asthma to increase mucociliary clearance and regulate surfactant levels, perhaps through anti-oxidant and anti-inflammatory activities. To determine the role and effect of ambroxol in an experimental model of asthma, BALB/c mice were sensitized to ovalbumin (OVA) followed by 3 days of challenge. Airway hyperresponsiveness (AHR), lung cell composition and histology, and cytokine and protein carbonyl levels in bronchoalveolar lavage (BAL) fluid were determined. Ambroxol was administered either before the first OVA challenge or was begun after the last allergen challenge. Cytokine production levels from lung mononuclear cells (Lung MNCs) or alveolar macrophages (AM) were also determined. Administration of ambroxol prior to challenge suppressed AHR, airway eosinophilia, goblet cell metaplasia, and reduced inflammation in subepithelial regions. When given after challenge, AHR was suppressed but without effects on eosinophil numbers. Levels of IL-5 and IL-13 in BAL fluid were decreased when the drug was given prior to challenge; when given after challenge, increased levels of IL-10 and IL-12 were detected. Decreased levels of protein carbonyls were detected in BAL fluid following ambroxol treatment after challenge. In vitro, ambroxol increased levels of IL-10, IFN-γ, and IL-12 from Lung MNCs and AM, whereas IL-4, IL-5, and IL-13 production was not altered. Taken together, ambroxol was effective in preventing AHR and airway inflammation through upregulation of Th1 cytokines and protection from oxidative stress in the airways.
Ambroxol*
;
Animals
;
Asthma
;
Bronchoalveolar Lavage
;
Cytokines
;
Eosinophilia
;
Eosinophils
;
Goblet Cells
;
In Vitro Techniques
;
Inflammation*
;
Interleukin-10
;
Interleukin-12
;
Interleukin-13
;
Interleukin-4
;
Interleukin-5
;
Lung
;
Macrophages, Alveolar
;
Metaplasia
;
Mice
;
Models, Theoretical
;
Mucociliary Clearance
;
Neutrophils
;
Ovalbumin
;
Ovum
;
Oxidative Stress
;
Pulmonary Disease, Chronic Obstructive
;
Up-Regulation
6.The Support in Opioid Introduction Period for Outpatients with Cancer by Palliative Care Staffs
Yoshihiro YAMAMOTO ; Hiroaki WATANABE ; Ayako KONDO ; Yuko DEGUCHI ; Shigeki HIRANO ; Aina SAKURAI ; Shoko KUMON ; Rumiko MURAJI ; Megumi MOTIYAMA ; Yoshimi OKUMURA ; Yasuyuki ASAI ; Takuya ODAGIRI
Palliative Care Research 2020;15(4):303-308
Introduction: Our palliative care staff began the support activity in opioid introduction for outpatients with cancer at Komaki City Hospital in March 2018, because it was difficult to make them understand about proper use of opioid analgesics and misinterpretation about abuse at the time of opioid introduction in outpatient settings. This study aimed to evaluate the effects of the activity (patient education on pain control, telephone follow up, and assessment of the symptom). Method: Outpatients with cancer receiving strong opioids for pain relief from January 2017 to March 2019 were eligible. We retrospectively investigated the difference of the variables between baseline and after the activity as follows; the ratios of prescribing immediate-release opioids, antiemetics, and laxatives when opioids were prescribed and side effects due to opioid analgesics appeared. Results: The study included 122 patients. The prescribing ratios of immediate-release opioids antiemetics and laxatives all increased from 90.7 to 98.5%, from 63.0 to 70.6%, and from 61.1 to 70.6%, respectively. The side effect incidence due to opioids with STAS-J 2 or more decreased from 12 (22.2%) to 9 (13.2%). Discussion: The activity could contribute to the provision of drug treatments and counselling needed for opioid therapy.